Novartis Discontinues Asthma Drug Development
December 16 2019 - 1:54AM
Dow Jones News
By Carlo Martuscelli
Novartis AG (NOVN.EB) said Monday that it will cease development
of its investigational asthma drug fevipiprant following
disappointing clinical data.
A pooled analysis of the Phase 3 Luster-1 and Luster-2 studies
showed that the therapy didn't meet the clinical threshold in the
reduction of moderate-to-severe asthma exacerbations when compared
with placebo, the company said. The drug was, however, found safe,
the Swiss drug maker said.
An analysis of safety and efficacy data from the two studies
will be conducted, and details will be published at an upcoming
medical conference, Novartis said.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com;
@carlomartu
(END) Dow Jones Newswires
December 16, 2019 01:39 ET (06:39 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024